The Pattern of P53 and p21WAF1/CIP1 Immunoreactivity in Non-Hodgkinʼs Lymphomas Predicts P53 Gene Status
- 1 August 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Diagnostic Molecular Pathology
- Vol. 6 (4) , 222-228
- https://doi.org/10.1097/00019606-199708000-00006
Abstract
P53 and p21WAF1/CIP1 (p21) immunostaining was performed on 92 non-Hodgkin's lymphomas (NHLs), and the staining pattern correlated with the presence or absence of p53 hot spot mutations as detected by PCR-SSCP of exons 5-8 and direct sequencing. Twenty-nine of 92 lymphomas overexpressed p53, and 17 overexpressed p21. Of the p53 overexpressing lymphomas, 14 also overexpressed p21, and none of these 14 harbored a detectable hot spot mutation. However, mutations were detected in 13 (87%) of 15 p53 overexpressing, p21 negative lymphomas. One of the 63 p53-negative lymphomas harbored a detectable hot spot mutation, and it was also negative for p21. These results demonstrate that among NHLs that overexpress p53 protein, those which also show p21 overexpression do not harbor p53 hot spot mutations, and furthermore, provide evidence that the transactivating function of p53 is retained. On the other hand, p53 overexpression in NHLs that lack p21 expression is usually indicative of p53 gene mutation. (C) Lippincott-Raven Publishers.Keywords
This publication has 20 references indexed in Scilit:
- A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce ApoptosisMolecular and Cellular Biology, 1996
- Genetic Status and Expression of the Cyclin‐dependent Kinase Inhibitors in Human Gastric Carcinoma Cell LinesJapanese Journal of Cancer Research, 1996
- p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survivalBritish Journal of Cancer, 1996
- Gene Therapy for Head and Neck Cancer: Comparing the Tumor Suppressor Gene p53 and a Cell Cycle Regulator WAF1/CIP1 (p21)JAMA Otolaryngology–Head & Neck Surgery, 1996
- mdm-2 Oncogene Expression in Non-Hodgkinʼs LymphomasDiagnostic Molecular Pathology, 1996
- Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint controlCell, 1995
- p53 mutation and expression in lymphomaBritish Journal of Cancer, 1995
- The MDM2 oncogene is rarely amplified in human lymphoid tumors and does not correlate with p53 gene expressionInternational Journal of Cancer, 1994
- p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.Proceedings of the National Academy of Sciences, 1991
- The p53 tumour suppressor geneNature, 1991